1 Min Read
March 22 (Reuters) - Shire Plc:
* Shire receives FDA fast track designation for Recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.